MARC details
| 000 -LEADER |
|---|
| fixed length control field |
07938nam a22003497i 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
220706s2022 ua a|||f bm|| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
EG-NcFUE |
| Transcribing agency |
EG-NcFUE |
| Modifying agency |
EG-NcFUE |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract/overprinted title or subtitle |
ara |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Edition number |
22 |
| Classification number |
620.5 |
| Item number |
E.M.D |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Elgendy, Mohamed Ahmed Emad Abdellatif |
| Relator term |
author. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Development and Optimization of Liquid Crystalline Nanostructures for Enhanced Ocular Delivery / |
| Statement of responsibility, etc |
by Mohamed Ahmed Emad Abdellatif Elgendy Assistant Lecturer at Department of Pharmaceutics and Pharmaceutical Technology Faculty of Pharmacy, Future University in Egypt ; supervisors : Prof. Dr. Nahed Daoud Mortada Professor of Pharmaceutics and Industrial Pharmacy Faculty of Pharmacy Ain Shams University, Prof. Dr. Mona Ibrahim Abdul Tawab Elassal Professor of Pharmaceutics and Pharmaceutical Technology Faculty of Pharmacy, Future University in Egypt, Prof. Dr. Rania Aziz Helmy Ishak Professor of Pharmaceutics and Industrial Pharmacy Faculty of Pharmacy Ain Shams University, Dr. Mai Mansour Soliman Lecturer of Pharmaceutics and Industrial Pharmacy Faculty of Pharmacy Ain Shams University. |
| 246 35 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
تطوير وتعظيم بلورات سائلة نانووية لتحسين التوصيل الدوائي للعين |
| 264 #0 - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Date of publication, distribution, etc |
2022 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
231 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
24 cm |
| 336 ## - CONTENT TYPE |
|---|
| Source |
rdacontent |
| Content type term |
text |
| Content type code |
txt |
| 337 ## - MEDIA TYPE |
|---|
| Source |
rdamedia |
| Media type term |
unmediated |
| Media type code |
n |
| 338 ## - CARRIER TYPE |
|---|
| Source |
rdacarrier |
| Carrier type term |
volume |
| Carrier type code |
nc |
| 500 ## - GENERAL NOTE |
|---|
| General note |
supervisors : Prof. Dr. Nahed Daoud Mortada Professor of Pharmaceutics and Industrial Pharmacy Faculty of Pharmacy Ain Shams University, Prof. Dr. Mona Ibrahim Abdul Tawab Elassal Professor of Pharmaceutics and Pharmaceutical Technology Faculty of Pharmacy, Future University in Egypt, Prof. Dr. Rania Aziz Helmy Ishak Professor of Pharmaceutics and Industrial Pharmacy Faculty of Pharmacy Ain Shams University, Dr. Mai Mansour Soliman Lecturer of Pharmaceutics and Industrial Pharmacy Faculty of Pharmacy Ain Shams University. |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (Ph.D.)--Ain Shams University, Faculty of pharmacy, Department of Pharmaceutics and Industrial Pharmacy,2022. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references (pages 197- 231). |
| 520 3# - SUMMARY, ETC. |
|---|
| Summary, etc |
Liquid crystalline nanostructures (LCNs), for instance cubosomes, have been<br/>widely used as a promising carrier for drug delivery through the last few years. To <br/>date, the ophthalmic application of these platforms is not well explored, and the <br/>effect of integrating penetration enhancers (PEs) into LCNs has not been <br/>investigated yet. Cubosomes mainly prepared using Glyceryl monooleate (GMO) or <br/>Phytantriol (PYT) as a lipid with the addition of Poloxamer 407 (P407) as a <br/>stabilizer. The integration of new stabilizers other than P407 is still limited in <br/>research. Thus, this thesis is divided into three chapters. <br/>LCNs were prepared using hot emulsification method by coupling of novel <br/>PEs at different amounts into GMO-based cubosomes for ocular administration. The <br/>morphology of the formed LCNs was investigated using transmission electron <br/>microscopy (TEM). The crystallinity and thermal behavior studies were also <br/>conducted. The acceptable formulations exhibited relatively homogenous particle <br/>nano-sizes ranging from 139.26 ± 3.68 to 590.56 ± 24.86 nm carrying negative <br/>surface charges. TEM images, X-ray patterns and DSC thermograms demonstrated <br/>the influential effect of PEs in developing altered crystalline structures. Hen’s egg <br/>test-chorioallantoic membrane (HET-CAM), rabbit eye Draize test, and <br/>histopathological examinations of ocular tissues confirmed the ocular compatibility <br/>of optimized LCNs. The corneal distribution using confocal laser scanning <br/>microscope (CLSM) proved the disseminated fluorescence intensity of LCNs <br/>enriched with oleic acid, Captex® 8000 and Capmul® MCM as enhancers. Selected <br/>LCNs showed good physical stability upon storage and lyophilization. <br/>Moreover, D-optimal design was applied to investigate the optimal LCNs <br/>composition for drug loading. A preliminary study was conducted to optimize the <br/>key formulation components of LCNs; Phytantriol (PYT) in comparison to GMO as <br/>lipids, and different stabilizers were compared to P407. This study aimed to set the <br/>type and the amount range of each component to be used later in the experimental <br/>design for optimization, where GMO, TPGS and Tween 80 were proven to be the <br/>most suitable for fabrication of optimized LCNs loaded with the anti-glaucomic <br/>drug, Travoprost (TRAVO). Optimum formulae were F-1-L and F-3-L both <br/>composed of 25 mg GMO (lipid), 25 mg Tween 80 (stabilizer) and 25 mg of oleic <br/>acid and Captex 8000 (PE), respectively. They showed PS of 216.20 ± 6.12 and <br/>129.40 ± 11.73 nm with PDI values of 0.27 ± 0.03 and 0.34 ± 0.03, respectively. The <br/>ZP values were -72.93 ± 1.97 and -17.55 ± 2.10 mV, and both formulae revealed <br/>high EE % of 85.30 ± 4.29 and 82.54 ± 7.65%, respectively. Furthermore, they<br/>showed the highest drug permeation profile during the ex-vivo studies.<br/>The pharmacodynamic (PD) and pharmacokinetic (PK) studies conducted on <br/>adult New Zealand White rabbits in addition to ocular tolerability and histological <br/>examinations showed that, F-1-L has achieved its lowest IOP (15.6 mmHg) at 6 h <br/>post-dose application and maintained its lowering effect for 48 h. On other hand, F3-L, showed the lowest IOP (13.9 mmHg) at 24 h after instillation and its effect <br/>lasted for the 72 h. At last, Travatan® (the market product) showed its lowest IOP <br/>(14.7 mm Hg) at 8 h and its effect was lasted for 36 h only. The LCN formula F-3-<br/>L showed a significant higher Cmax of 1.80 ± 0.15 ng/ml (p<0.05), when compared <br/>to 1.46 ± 0.06 and 1.42 ± 0.09 ng/ml obtained in case of F-1-L and Travatan®, <br/>respectively. The highest median Tmax of 6 h attained by F-3-L confirmed the more <br/>controlled drug permeation behavior than those achieved by Travatan® and F-1-L <br/>recording 1 and 2 h, respectively. Furthermore, the chosen formulation F-3-L <br/>showed significant higher AUC0-48, AUCinf and MRT of 62.77 ± 2.73 ng.h/ml, <br/>406.69 ± 17.12 ng.h/ml and 23.18 ± 0.57 h in comparison to the respective data <br/>obtained from F-1-L and Travatan® 43.02 ± 2.97 and 11.58 ± 0.23 ng.h/ml, 133.63<br/>± 11.54 and 125.98 ± 8.54 ng.h/ml, 11.73 ± 0.22 and 11.58 ± 0.23 h. The <br/>bioavailability of both formulae relative to the market product TRAVATAN® was <br/>also calculated, as F-1-L showed a relative bioavailability of 106.1%, while F-3-L <br/>showed a much higher value of 322.82% with respect to the market product. All the <br/>tested LCNs did not show any signs of ocular damage or clinical abnormalities <br/>compared to the control eye as observed. The current thesis described the successful <br/>incorporation of a novel PE (Captex®8000) into conventional LCNs. Furthermore, <br/>TRAVO loading in such liquid crystals stabilized with Tween 80 resulted in a safe <br/>and effective ocular drug delivery system for glaucoma treatment. The prepared <br/>LCNs demonstrated favorable penetration power throughout the corneal layer, as <br/>well as good stability and high TRAVO entrapment efficiency. While instilling the <br/>same drug dose, the bioavailability of TRAVO was increased three-folds when <br/>delivered using LCNs relative to the market product Travatan®, confirming the <br/>superiority of the tailored TRAVO-LCNs in the management of glaucoma. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
Text in English, abstract in English and Arabic. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Nanostructures. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Nanotechnology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Nanostructures |
| General subdivision |
Industrial applications. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Mortada, Nahed Daoud |
| 9 (RLIN) |
33955 |
| Relator term |
supervisor |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Elassal, Mona Ibrahim Abdul Tawab |
| 9 (RLIN) |
33956 |
| Relator term |
supervisor |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ishak, Rania Aziz Helmy |
| 9 (RLIN) |
33957 |
| Relator term |
supervisor |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Soliman, Mai Mansour |
| 9 (RLIN) |
33958 |
| Relator term |
supervisor |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
http://repository.fue.edu.eg/xmlui/handle/123456789/6059 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Item type |
Thesis |